Patents by Inventor Jeffrey Strovel

Jeffrey Strovel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9446021
    Abstract: Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/?-catenin signaling pathway, and serve to reduce ?-catenin levels present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: September 20, 2016
    Assignee: Dogwood Pharmaceuticals, Inc.
    Inventors: Wieslaw M. Cholody, Yi Zang, Karina Zuck, Jeffrey W. H. Watthey, Zoe Ohler, Jeffrey Strovel, Gene Ohler, Sheela Chellappan, Janak Padia
  • Publication number: 20150313873
    Abstract: Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/?-catenin signaling pathway, and serve to reduce ?-catenin levels present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.
    Type: Application
    Filed: July 9, 2015
    Publication date: November 5, 2015
    Inventors: Wieslaw M. Cholody, Yi Zang, Karina Zuck, Jeffrey W.H. Watthey, Zoe Ohler, Jeffrey Strovel, Gene Ohler, Sheela Chellappan, Janak Padia
  • Patent number: 9120754
    Abstract: Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/?-catenin signaling pathway, and serve to reduce ?-catenin levels present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: September 1, 2015
    Assignee: Dogwood Pharmaceuticals, Inc.
    Inventors: Wieslaw M. Cholody, Yi Zang, Karina Zuck, Jeffrey W. H. Watthey, Zoe Ohler, Jeffrey Strovel, Gene Ohler, Sheela Chellappan, Janak Padia
  • Publication number: 20120129837
    Abstract: Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/?-catenin signaling pathway, and serve to reduce ?-catenin levels present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.
    Type: Application
    Filed: January 30, 2012
    Publication date: May 24, 2012
    Inventors: Wieslaw M. Cholody, Yi Zang, Norman E. Ohler, Sheela Chellappan, Janak Padia, Karina Zuck, Jeffrey W.H. Watthey, Zoe Ohler, Jeffrey Strovel
  • Patent number: 8129519
    Abstract: Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/?-catenin signaling pathway, and serve to reduce ?-catenin levels present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: March 6, 2012
    Inventors: Wieslaw M. Cholody, Yi Zang, Karina Zuck, Jeffrey W. H. Watthey, Zoe Ohler, Jeffrey Strovel, Norman E. Ohler, Sheela Chellappan, Janak Padia
  • Publication number: 20100249111
    Abstract: Chemical agents, such as derivatives of hydroxy benzene moieties, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of enzymes and structural polypeptides present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.
    Type: Application
    Filed: April 25, 2008
    Publication date: September 30, 2010
    Applicant: AVALON PHARMACEUTICALS
    Inventors: Norman E. Ohler, Jeffrey W. Watthey, Jeffrey Strovel, Sheela K. Chellappan
  • Publication number: 20100137354
    Abstract: Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/?-catenin signaling pathway, and serve to reduce ?-catenin levels present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.
    Type: Application
    Filed: May 9, 2008
    Publication date: June 3, 2010
    Inventors: Wieslaw M. Cholody, Yi Zang, Karina E. Zuck, Jeffrey W.H. Watthey, Zoe Ohler, Jeffrey Strovel, Norman E. Ohler, Sheela K. Chellappan, Janak Padia
  • Publication number: 20080025981
    Abstract: Cancer-linked gene sequences, and derived amino acid sequences, are disclosed along with methods for assaying for potential antitumor agents based on their modulation of the expression of these cancer-related genes. Also disclosed are antibodies that react with the disclosed polypeptides and methods of using the antibodies to treat cancerous conditions, such as using the antibody to target cancerous cells in vivo for purposes of delivering therapeutic agents thereto. Also described are methods of diagnosing cancer using the gene sequences as well as the polypeptide sequences.
    Type: Application
    Filed: November 15, 2006
    Publication date: January 31, 2008
    Inventors: Paul Young, Reinhard Ebner, Zoe Weaver, Jeffrey Strovel, Stephen Horrigan, Martin Shea, Bernd Weigle, Michael Rieger, Jennifer Rick, Colyn Cain
  • Publication number: 20070184447
    Abstract: Methods for the identification of disease-related gene sets and expression nprofiles, based on common chemical modulation using a specific chemical compound are disclosed.
    Type: Application
    Filed: February 24, 2005
    Publication date: August 9, 2007
    Inventors: Jeffrey Strovel, David Bol, Paul Young
  • Publication number: 20070059697
    Abstract: Methods for identifying potential therapeutic agents, such as anti-tumor agents, based on their modulation of the expression of specified genes, especially genes mapping to specific chromosomal regions, are disclosed. Also described are methods for diagnosing cancerous, or potentially cancerous, conditions as a result of the expression, or patterns of expression, of such genes, including detecting changes in levels of gene copy number and/or level of amplification of the said gene, or sets of genes, to detect and/or diagnose the cancer. Methods for detecting or determining functionally related genes, as well as methods for treating cancer based on targeting expression products of such genes, determining genes involved in the cancerous process and the success and/or response rates and survival statistics for cancer patients on treatment are encompassed by the invention.
    Type: Application
    Filed: April 15, 2004
    Publication date: March 15, 2007
    Applicant: AVALON PHARMACEUTICALS, INC
    Inventors: Jeffrey Strovel, Colyn Cain, Stephen Horrigan, Meena Augustus
  • Publication number: 20060134622
    Abstract: A gene useful as a prognostic indicator of survival of patients afflicted with cancers such as breast cancer is described. Also disclosed are methods for screening potential therapeutic agents, such as antitumor agents, based on their modulation of the expression of a TRIP13 gene, or splice variants thereof, along with methods for diagnosing cancerous, or potentially cancerous, conditions as a result of the expression, or patterns of expression, of such genes, including changes in copy number. Also disclosed are methods for detecting or determining functionally related genes, where disruption of TRIP13 may affect such related-gene expression, as well as methods for treating cancer based on targeting expression products of such genes and determining genes involved in the cancerous process.
    Type: Application
    Filed: December 19, 2003
    Publication date: June 22, 2006
    Inventors: Meena Augustus, Stephen Horrigan, Colyn Cain, Jeffrey Strovel